Improved methods to determine tumor localization and disease extension are critical factors in the management of pancreatic ductal adenocarcinoma (PDAC). Thus, contrast-enhanced fluorescence-guided detection of these lesions could improve the treatment of PDAC. A current limitation to fluorescence enhancement of PDAC is non-specific signal due to the clearance of the imaging dye, e.g. indocyanine green, like the liver, spleen or other local, intraperitoneal organs where metastatic spread may be present. We report surgical imaging agents that provide strong enhancement of PDAC compared to healthy tissue, but also have significantly reduced nonspecific background signal in clearance organs of the peritoneal cavity.
|